Express News | Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
Organovo Announces the Issuance of Additional Shares in Conjunction With Warrant Exercises
Organovo Announces Issuance of Additional 3M Shares in Conjunction With Warrant Exercises
Eli Lilly and Co (LLY.US) acquired the FXR project and its main therapy FXR314 from Organovo, aimed at treating ulcerative colitis.
Currently, Organovo has obtained clinical trial approval from the USA FDA and is conducting its Phase 2 trial for its flagship therapy FXR314 for the treatment of ulcerative colitis (UC).
Sector Update: Health Care Stocks Higher Late Afternoon
Eli Lilly Expands Zepbound Vial Dose Options, Cuts Weight-Loss Drug's Prices for Self-Pay Patients
Top Midday Gainers
Trending Stocks Today | Organovo Holdings Surges 306.5%
February 25th - US stocks trending in regular trading hours.Gainers: $Organovo Holdings(ONVO.US)$ soars 306.5% to $1.5 with a turnover of $243.45 million. $Wah Fu Education(WAFU.US)$ surges 164.24%
Why Organovo (ONVO) Stock Is Skyrocketing
Organovo Holdings Shares Halted On Circuit Breaker To The Downside, Stock Now Up 214.4%
Express News | Organovo’s Fxr Program, Including Fxr314, to Be Acquired by Eli Lilly and Company
Organovo's FXR Program, Including FXR314, to Be Acquired by Eli Lilly and Company
Organovo Holdings | 10-Q: Q3 2025 Earnings Report
Organovo Holdings Delays Quarterly Report Filing
Earnings Week Ahead: PLTR, AMZN, GOOG, AMD, LLY, PEP, F, PFE, MRK, PYPL and More
Executive Reshuffles: META, LUV, CCI and WPM
Press Release: Organovo Announces Appointment of Norman Staskey as Chief Financial Officer
Express News | Organovo Holdings Inc - Appoints Norman Staskey as President and CFO
Organovo Holdings Gains Approval for Key Strategic Moves
Organovo Highlights Phase 2 Results For FXR314 In MASH At The Liver Meeting, Showing Significant Liver Fat Reduction And Improved Safety Profile Compared To Other FXR Agonists